Blackstone is Exploring the Sale of Anthos Therapeutics

Private equity firm Blackstone Inc BX.N is exploring the sale of Anthos Therapeutics, a developer of a new generation of blood thinners it launched four years ago with backing from Novartis AG NOVN.S, according to people familiar with the matter.

Anthos, which does not generate any revenue because its products have not yet hit the market, could be worth several billion dollars in a potential sale, significantly more than the $250 million that Blackstone invested when it founded Anthos in 2019, the sources said. The company’s anticoagulants have made significant progress in late-stage clinical trials, the sources added.

Cambridge, Massachusetts-based Anthos’ most advanced product, a monoclonal antibody called abelacimab, is intended for patients with atrial fibrillation who do not respond well to other anticoagulants because of heavy bleeding.

Read the source article at Nasdaq